Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt Acquires 15,000 Shares

Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt acquired 15,000 shares of Immunic stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average cost of $0.77 per share, for a total transaction of $11,550.00. Following the completion of the purchase, the chief executive officer now owns 29,000 shares in the company, valued at approximately $22,330. The trade was a 107.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $0.79 on Friday. Immunic, Inc. has a 52-week low of $0.56 and a 52-week high of $2.11. The business’s 50 day simple moving average is $0.96 and its two-hundred day simple moving average is $1.05. The firm has a market cap of $75.54 million, a P/E ratio of -0.64 and a beta of 1.73.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.25). On average, equities analysts forecast that Immunic, Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Aberdeen Group plc bought a new stake in shares of Immunic during the first quarter worth about $1,155,000. Millennium Management LLC boosted its stake in Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the last quarter. Focus Partners Wealth increased its holdings in Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after purchasing an additional 415,104 shares in the last quarter. 683 Capital Management LLC raised its stake in shares of Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. B. Riley reaffirmed a “buy” rating and set a $5.00 price target (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Thursday, May 1st. William Blair restated an “outperform” rating on shares of Immunic in a report on Friday, May 16th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus price target of $11.60.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.